Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)
- PMID: 37212947
- DOI: 10.1007/s12032-023-02053-2
Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)
Abstract
Non-Small Cell Lung Cancer (NSCLC) is the leading cause of death in all countries alike. In the current study, we have found out that Histone H3Lys4trimethylation is abnormal on YY1 in CD4+T Helper (TH) cells of NSCLC patients which is evident by Histone H3Lys27 trimethylation mediated via EZH2. We investigated the status of Yin Yang 1 (YY1) and the involvement of certain transcription factors that lead to tumorigenesis after depleting endogenous EZH2 in vitro by CRISPR/Cas9 in the CD4+TH1-or-TH2-polarized cells isolated initially as CD4+TH0 cells from the PBMC of the control subjects and patients suffering from NSCLC. After depletion of endogenous EZH2, RT-qPCR based mRNA expression analysis showed that there was an increase in the expression of TH1 specific genes and a decrease in the expression of TH2 specific genes in NSCLC patients CD4+TH cells. We can conclude that this group of NSCLC patients may have the tendency at least in vitro to elucidate adaptive/protective immunity through the depletion of endogenous EZH2 along with the reduction in the expression of YY1. Moreover, depletion of EZH2 not only suppressed the CD4+CD25+FOXP3+Regulatory T cells (Treg) but also it aided the generation of CD8+Cytotoxic T Lymphocytes (CTL) which were involved in killing of the NSCLC cells. Thus the transcription factors involved in EZH2 mediated T cell differentiation linked to malignancies offers us an appealing avenue of _targeted therapeutic intervention for NSCLC.
Keywords: EZH2; NSCLC; T cell differentiation; Transcription factors; YY1.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.Pathol Res Pract. 2023 Nov;251:154885. doi: 10.1016/j.prp.2023.154885. Epub 2023 Oct 10. Pathol Res Pract. 2023. PMID: 37862922 Review.
-
Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.J Pathol. 2016 Apr;238(5):651-64. doi: 10.1002/path.4688. J Pathol. 2016. PMID: 26800240
-
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13. Cancer Sci. 2016. PMID: 27116120 Free PMC article.
-
Polycomb recruitment at the Class II transactivator gene.Mol Immunol. 2015 Oct;67(2 Pt B):482-91. doi: 10.1016/j.molimm.2015.08.003. Epub 2015 Aug 15. Mol Immunol. 2015. PMID: 26283540
-
Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases.Crit Rev Immunol. 2019;39(6):491-510. doi: 10.1615/CritRevImmunol.2020033272. Crit Rev Immunol. 2019. PMID: 32421959 Review.
Cited by
-
Transcription factor Yin Yang 1 enhances epithelial-mesenchymal transition, migration, and stemness of non-small cell lung cancer cells by _targeting sonic hedgehog.Mol Cell Biochem. 2024 Sep 11. doi: 10.1007/s11010-024-05104-y. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39261409
References
-
- Chen B, Zeng C, Ye Y, et al. Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer. J Cell Commun Signal. 2018;12:423–32. https://doi.org/10.1007/s12079-017-0418-2 . - DOI - PubMed
-
- Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. https://doi.org/10.21037/tlcr.2016.06.07 . - DOI - PubMed - PMC
-
- Sharma S, Kelly T, Jones P. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36. https://doi.org/10.1093/carcin/bgp220 . - DOI - PubMed - PMC
-
- Pandya P, Murray M, Pollok K, Renbarger J. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res. 2016;4273943:1–13. https://doi.org/10.1155/2016/4273943 . - DOI
-
- Yu J, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007;12(5):419–31. https://doi.org/10.1016/j.ccr.2007.10.016 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials